342 related articles for article (PubMed ID: 28521962)
1. The functional roles of PML nuclear bodies in genome maintenance.
Chang HR; Munkhjargal A; Kim MJ; Park SY; Jung E; Ryu JH; Yang Y; Lim JS; Kim Y
Mutat Res; 2018 May; 809():99-107. PubMed ID: 28521962
[TBL] [Abstract][Full Text] [Related]
2. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
3. Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Yeung PL; Denissova NG; Nasello C; Hakhverdyan Z; Chen JD; Brenneman MA
J Cell Biochem; 2012 May; 113(5):1787-99. PubMed ID: 22213200
[TBL] [Abstract][Full Text] [Related]
4. PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.
di Masi A; Cilli D; Berardinelli F; Talarico A; Pallavicini I; Pennisi R; Leone S; Antoccia A; Noguera NI; Lo-Coco F; Ascenzi P; Minucci S; Nervi C
Cell Death Dis; 2016 Jul; 7(7):e2308. PubMed ID: 27468685
[TBL] [Abstract][Full Text] [Related]
5. Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
Voisset E; Moravcsik E; Stratford EW; Jaye A; Palgrave CJ; Hills RK; Salomoni P; Kogan SC; Solomon E; Grimwade D
Blood; 2018 Feb; 131(6):636-648. PubMed ID: 29191918
[TBL] [Abstract][Full Text] [Related]
6. [Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].
Hao R; Su L; Shao Y; Bu N; Ma L; Naranmandura H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2018 May; 47(5):541-551. PubMed ID: 30693698
[TBL] [Abstract][Full Text] [Related]
7. Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
Hirano S; Udagawa O
PLoS One; 2022; 17(5):e0268835. PubMed ID: 35594310
[TBL] [Abstract][Full Text] [Related]
8. Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia.
Xu T; Yang XQ; Jiang KL; Wang H; Ma PP; Zhong L; Liu BZ
Oncol Rep; 2017 Feb; 37(2):986-994. PubMed ID: 28075463
[TBL] [Abstract][Full Text] [Related]
9. Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL.
Shao X; Chen Y; Xu A; Xiang D; Wang W; Du W; Huang Y; Zhang X; Cai M; Xia Z; Wang Y; Cao J; Zhang Y; Yang B; He Q; Ying M
Cell Death Differ; 2022 Aug; 29(8):1654-1668. PubMed ID: 35194189
[TBL] [Abstract][Full Text] [Related]
10. Role of nuclear bodies in apoptosis signalling.
Krieghoff-Henning E; Hofmann TG
Biochim Biophys Acta; 2008 Nov; 1783(11):2185-94. PubMed ID: 18680765
[TBL] [Abstract][Full Text] [Related]
11. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
Shen H; Maki CG
J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
[TBL] [Abstract][Full Text] [Related]
12. PML nuclear body-residing proteins sequentially associate with HPV genome after infectious nuclear delivery.
Guion L; Bienkowska-Haba M; DiGiuseppe S; Florin L; Sapp M
PLoS Pathog; 2019 Feb; 15(2):e1007590. PubMed ID: 30802273
[TBL] [Abstract][Full Text] [Related]
13. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
14. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
15. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
16. PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?
Brown NJ; Ramalho M; Pedersen EW; Moravcsik E; Solomon E; Grimwade D
Front Biosci (Landmark Ed); 2009 Jan; 14(5):1684-707. PubMed ID: 19273155
[TBL] [Abstract][Full Text] [Related]
17. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
18. PML Nuclear bodies: the cancer connection and beyond.
Abou-Ghali M; Lallemand-Breitenbach V
Nucleus; 2024 Dec; 15(1):2321265. PubMed ID: 38411156
[TBL] [Abstract][Full Text] [Related]
19. Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells.
Hirano S; Udagawa O; Kobayashi Y; Kato A
Toxicol Appl Pharmacol; 2018 Dec; 360():150-159. PubMed ID: 30292834
[TBL] [Abstract][Full Text] [Related]
20. PML-RARα stabilized by zinc in human acute promyelocytic leukemia NB4 cells.
Zhu B; Wang JY; Zhou JJ; Zhou F; Cheng W; Liu YT; Wang J; Chen X; Chen DH; Luo L; Hua ZC
J Inorg Biochem; 2017 Oct; 175():92-100. PubMed ID: 28743050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
